Search results for

null

Prudence Malinki and Steve Miholovich of Safenames examine some of the history of the UDRP, offer 10 tips on best practices for domain name cases and speculate on future challenges

Many African countries are reforming IP laws adopted under colonialism to bring them in line with WIPO and WTO norms, explains Mac Spence of Spoor & Fisher Jersey

Former IBM VP and assistant general counsel David Kappos was sworn in as the new director of the USPTO on August 7. While he has been embraced by the IP community, he faces a host of challenges, including a major funding crisis sparked by a sharp drop in filings. Eileen McDermott reports

With the appointment of former IBM VP and assistant general counsel David Kappos as the new director of the USPTO, the US – and perhaps global – IP community has something to cheer about this year. Kappos has a tough job ahead of him, but most seem confident in his abilities and are excited by his 20 years of experience in the patent world. In the editorial introduction to the 2009 edition of the Americas IP Focus, we track Kappos' road to the USPTO and report on the reaction to some of his first public promises to the IP community.

Yumari Torres de Guerra and Deborah Guzmán I. provide an update on the state of IP rights and enforcement in the Dominican Republic

Andrew Moeser analyses the Supreme Court's recent Sanofi decision in the light of case law on obviousness in the US and UK

null

Effective management of pharmaceutical and biotechnology inventions involves considering issues such as patentability, data protection, enforcement, experimental use and branding. Christine Kanz and Anja Lunze of Reimann Osterrieth Köhler Haft explain how these issues are addressed in Germany

Pharmaceutical companies strategies have come under scrutiny from the European Commission in the past year. Edward Nodder and Maria Isabel Manley of Bristows in London explain why effective life-cycle management of pharmaceutical products is essential for a successful industry